Compare Capital One Financial Corp. (COF) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Capital One Financial Corp. vs Neurocrine Biosciences Inc — how do they compare? Capital One Financial Corp. trades at $219.35 (market cap $134.45B), while Neurocrine Biosciences Inc trades at $151.75 (market cap $16.46B). The key difference: Capital One Financial Corp. is far larger — about 8.2× Neurocrine Biosciences Inc's market cap, and Capital One Financial Corp. pays a 1.46% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| COF | NBIX | |
|---|---|---|
Market Cap | $134.45B | $16.46B |
Sector | Financials | Health |
52-Week High | $257.94 | $185.50 |
52-Week Low | $176.10 | $123.10 |
Dividend Yield | 1.46% | — |
Enterprise Value | — | $16.48B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Capital One Financial Corp.
Capital One is a diversified financial services holding company headquartered in McLean, Virginia. Originally a spinoff of Signet Financial's credit card division in 1994, the company is now primarily involved in credit card lending, auto loans, and commercial lending.
Read more on COF →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
